fashion -WSS

fashion

author：hotspot 2025-09-07 17:29:58 - browse：3

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Adam's Biotech Scorecard: Do Sarepta's exon

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

It's been 20 years since Dolly the sheep. Where's my clone?

Biohaven protein

iTeos Therapeutics debuts first data on TIGIT

Addiction doctors spar with methadone clinics over legislation

Drug for rare kidney disease narrowly misses mark in clinical trial

focus

fashion

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Do more moles mean more problems? Not so, says new study

What does generative AI mean for health care? We asked experts

Startling documents reveal new facets of Sacklers' opioid empire

Guidelines to prevent youth baseball injuries need more muscle

Akili, maker of video game for ADHD, to be acquired for 34 million

New air purifier tech could be key to improving indoor air quality

Medical student insurance fails on mental health care coverage

After affirmative action ruling, medical educators look to 'holistic review'

CDC's new outbreak response network to include Northeastern

leisure time

Biotech stock slump in 2023: awaiting the turnaround

Microbiome research is starting to find links to chronic diseases

Drug for rare kidney disease narrowly misses mark in clinical trial

David Sabatini, ex

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

entertainment

hotspot

focus

entertainment